Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in CALGB 89803 (Alliance)
Creators
- 1. Brown University
- 2. Dana-Farber Cancer Institute
- 3. Duke University Medical Center
- 4. Memorial Sloan-Kettering Cancer Center
- 5. Toledo Community Hospital Oncology Program
- 6. Hôpital du Sacré-Coeur de Montréal
- 7. Loyola University Stritch School of Medicine
- 8. Northwestern University
- 9. Virginia Oncology Associates
- 10. Southeast Cancer Control Consortium
- 11. University of Chicago
- 12. University of California at San Francisco Comprehensive Cancer Center
- 13. Harvard University
Description
Background: In colon cancer patients, obesity, sedentary lifestyle, and high dietary glycemic load have been associated with increased risk of cancer recurrence. High sugar-sweetened beverage intake has been associated with obesity, diabetes, and cardio-metabolic diseases, but the influence on colon cancer survival is unknown.
Methods: We assessed the association between sugar-sweetened beverage consumption on cancer recurrence and mortality in 1,011 stage III colon cancer patients who completed food frequency questionnaires as part of a U.S. National Cancer Institute-sponsored adjuvant chemotherapy trial. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated with Cox proportional hazard models.
Results: Patients consuming ≥2 servings of sugar-sweetened beverages per day experienced an adjusted HR for disease recurrence or mortality of 1.67 (95% CI, 1.04–2.68), compared with those consuming <2 servings per month (Ptrend = 0.02). The association of sugar-sweetened beverages on cancer recurrence or mortality appeared greater among patients who were both overweight (body mass index ≥25 kg/m2) and less physically active (metabolic equivalent task-hours per week <18) (HR = 2.22; 95% CI, 1.29–3.81, Ptrend = 0.0025).
Conclusion: Higher sugar-sweetened beverage intake was associated with a significantly increased risk of cancer recurrence and mortality in stage III colon cancer patients.
Data availability
The authors confirm that all data underlying the findings are fully available without restriction. Data held by the NCI ALLIANCE cooperative group. Contact Alliance Publications [publications@alliancenctn.org].Files
journal.pone.0099816.pdf
Files
(877.0 kB)
| Name | Size | Download all |
|---|---|---|
|
Article md5:a9db29777a2046b882dc560aaf954d67 |
877.0 kB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1371/journal.pone.0099816
- Other
- oai:uchicago.tind.io:8358
Funding
- National Cancer Institute
- CA31946
- Pharmacia & Upjohn Company
- National Cancer Institute
- R01 CA118553
- National Cancer Institute
- R01 CA149222
- National Cancer Institute
- R01 CA169141
- National Cancer Institute
- P50 CA127003